Brenntag (XTRA:BNR) reported second quarter 2026 earnings that caught investor attention, with sales of €4,263 million and net income of €179 million, compared with €3,869 million and €42 million a year earlier.
See our latest analysis for Brenntag.
Brenntag’s recent earnings release comes after a period of firm share price momentum, with a year to date share price return of 24.38% and a 1 year total shareholder return of 16.91%, despite weaker total shareholder returns over 3 and 5 years.
If Brenntag’s move has you looking beyond chemicals distribution, this is a good moment to scan the market for other trends using the 110 top founder-led companies
Brenntag now trades higher after stronger quarterly earnings, while longer term returns have lagged. Does the current valuation still offer an attractive balance of potential upside against the risks you would be taking on today?
Most Popular Narrative: 9.3% Overvalued
Brenntag’s most followed narrative currently points to a fair value of €56.43, which sits below the last close of €61.68 and frames the stock as slightly rich.
Brenntag continues to expand in higher-growth and higher-margin specialty chemical segments, exemplified by its entry into the rapidly growing biopharma market in EMEA via the MCE Pharma acquisition. This ongoing portfolio shift toward specialty chemicals and value-added services positions the company to capture resilient earnings and improve net margins over the long term.
Want to see what kind of revenue mix, margin uplift and profit multiple this narrative is banking on over the next few years? The underlying model leans on moderate growth, firmer profitability and a valuation profile that some investors usually associate with faster growing sectors.
Result: Fair Value of €56.43 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Brenntag still faces risks if geopolitical or trade disruptions weigh on demand, or if rising competition in regions like Latin America and APAC pressures margins.
Find out about the key risks to this Brenntag narrative.
Another View: Brenntag Through A Cash Flow Lens
The analyst narrative frames Brenntag as around 9.3% overvalued at €56.43 based on earnings and multiples. Our DCF model tells a very different story, with an estimated future cash flow value of €124.50 that is far above the current €61.68 share price. Which lens do you trust more for your own work?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Brenntag for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 270 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment split between upside potential and real concerns, this is a good time to dig into the details for yourself and judge Brenntag on your own terms. To help balance both sides, take a close look at the 3 key rewards and 1 important warning sign
Looking For More Ideas Beyond Brenntag?
If Brenntag has sharpened your focus on portfolio quality, now is the moment to widen your search with targeted screeners that surface clear, data driven ideas fast.
- Target potential mispricings by zeroing in on companies highlighted through the 270 high quality undervalued stocks.
- Strengthen your income stream by scanning reliable payers with the 448 dividend fortresses.
- Dial down risk by filtering for resilient businesses using the 283 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com